SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-008113
Filing Date
2023-05-04
Accepted
2023-05-04 16:15:43
Documents
68
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q knsa-20230331x10q.htm   iXBRL 10-Q 1940398
2 EX-31.1 knsa-20230331xex31d1.htm EX-31.1 11326
3 EX-31.2 knsa-20230331xex31d2.htm EX-31.2 10482
4 EX-32.1 knsa-20230331xex32d1.htm EX-32.1 6289
5 EX-32.2 knsa-20230331xex32d2.htm EX-32.2 6263
  Complete submission text file 0001558370-23-008113.txt   7308029

Data Files

Seq Description Document Type Size
6 EX-101.SCH knsa-20230331.xsd EX-101.SCH 51215
7 EX-101.CAL knsa-20230331_cal.xml EX-101.CAL 48883
8 EX-101.DEF knsa-20230331_def.xml EX-101.DEF 250376
9 EX-101.LAB knsa-20230331_lab.xml EX-101.LAB 445978
10 EX-101.PRE knsa-20230331_pre.xml EX-101.PRE 354614
62 EXTRACTED XBRL INSTANCE DOCUMENT knsa-20230331x10q_htm.xml XML 1158339
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 7814399100
Kiniksa Pharmaceuticals, Ltd. (Filer) CIK: 0001730430 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38492 | Film No.: 23888946
SIC: 2834 Pharmaceutical Preparations